cd19/bcma car t-cells
POEMS Syndrome
Zhejiang UniversityCell therapyEarly Phase 1Active
C
39/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 95/ 100
Competitive context
4 Active assets in the POEMS Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Tongji Hospital | Early Phase 1 | C |
Bcma Car T Cells Zhejiang University | Early Phase 1 | C |
Cyclophosphamide Tongji Hospital | Early Phase 1 | C |
ct103a cells Tongji Hospital | Early Phase 1 | C |
Same molecule, other indications
cd19/bcma car t-cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →